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In the United States, community-acquired pneumonia (CAP) accounts for 15.6 million cases and 1 million hospitalizations annually [1] . A retrospective cohort within 18 months [4] . Accordingly, institution of appropriate antibiotic therapy is imperative for elderly patients, to prevent unnecessary morbidity and death [3, [5] [6] [7] [8] .
Updated CAP treatment guidelines recommend fluoroquinolone monotherapy or b-lactam plus macrolide combination therapy for hospitalized patients with CAP [9, 10] . However, no prospective clinical trials have been published that compare fluoroquinolones in hospitalized elderly patients with CAP. Thus, the primary purpose of this study was to compare the efficacy of sequential intravenous/oral moxifloxacin therapy with levofloxacin therapy in hospitalized elderly patients aged у65 years with CAP. A separate publication involving this same patient population and protocol describes the primary safety variable (i.e., cardiac adverse events) [11] .
PATIENTS AND METHODS

Study design and treatment.
A prospective, randomized controlled, double-blind, double-dummy, comparative study was conducted from November 2002 to April 2004 at 47 study centers in the United States. The study was conducted in accordance with the Declaration of Helsinki, and each institution's internal review board approved the study protocol; written informed consent was obtained from each patient.
After stratification by disease severity with the revised American Thoracic Society criteria (mild/moderate vs. severe) [10] , patients were randomly assigned to receive either intravenous moxifloxacin, 400 mg once daily, or intravenous levofloxacin, 500 mg once daily, for 7-14 days. Patients were also assigned a Pneumonia Outcome Research Team pneumonia severity index score [12] , although it was not used for stratification. For patients with a documented and/or a calculated creatinine clearance rate of 20-49 mL/min, the intravenous dose of levofloxacin therapy was a 500-mg loading dose, followed by a dosage of 250 mg once daily for 7-14 days. Treatment with moxifloxacin did not require dosage adjustment for these patients.
Patients could be switched to oral therapy at the investigator's discretion (moxifloxacin, 400 mg once daily, or levofloxacin, 250-500 mg once daily) after у2 days of intravenous therapy if they demonstrated improvement during intravenous therapy, were afebrile for у8 h, and could tolerate oral food, fluids, and medications without vomiting or diarrhea. Both oral medications were encapsulated for blinding.
Patient population. The trial population included hospitalized elderly patients (age, у65 years) with clinical signs and symptoms of CAP, radiologically confirmed evidence of a new and/or progressive infiltrate(s), a requirement for initial parenteral therapy, and at least 2 of the following conditions: productive cough with purulent and/or mucopurulent sputum (у25 polymorphonuclear neutrophils per low-power field) or a change in sputum character (increased volume and/or purulence), dyspnea and/or tachypnea (respiratory rate of 120 breaths/min), rigors and/or chills, pleuritic chest pain, auscultatory findings of rales and/or crackles on pulmonary examination and/or evidence of pulmonary consolidation, fever ( ). Patients with any of the following characteristics were excluded from the study: hospitalization for 148 h before pneumonia development, end-organ damage or shock (systolic blood pressure of !90 mm Hg and diastolic blood pressure of !60 mm Hg) with need for vasopressors for 14 h, need for mechanical ventilation, implanted cardiac defibrillator, significant bradycardia (heart rate of !50 beats/min), systemic antibacterial therapy for 124 h within 7 days of enrollment unless therapy failed after receiving 172 h of a nonfluoroquinolone antibiotic, mechanical endobronchial obstruction, known or suspected active tuberculosis or endemic fungal infection, neutropenia (neutrophil count of !1000 neutrophils/mL), chronic therapy (duration of у2 weeks) with immunosuppressant therapy (115 mg/day of systemic prednisone or equivalent), known HIV infection (CD4 cell count of !200 cells/mm 3 ), severe hepatic insufficiency (Child-Pugh classification of C), renal impairment (serum creatinine clearance rate of !20 mL/min), uncorrected hypokalemia, known prolongation of the corrected QT interval or use of class IA or class III antiarrhythmics, previous history of tendinopathy with quinolones, or known hypersensitivity to study medications.
Clinical and bacteriologic evaluations. Clinical signs and symptoms were evaluated before treatment (within 48 h before receipt of the first dose of study drug), during treatment (between days 3 and 5 after the start of treatment), and at the test-of-cure visit (between days 5 and 21 after the end of therapy). Sputum samples were collected before study drug was started. Cultures were performed if Gram staining revealed р10 squamous epithelial cells per low-power field and у25 leukocytes per low-power field. Additional sputum specimens were obtained from patients with clinical failure. Blood specimens were obtained at enrollment, and if results of culture were positive, samples were obtained and cultured every 48 h until results were negative. A urinary antigen test for detection of Legionella pneumophila was performed.
Clinical and bacteriologic outcome definitions. Clinical response at the test-of-cure visit (between days 5 and 21 after the end of therapy) was the primary efficacy outcome. Secondary efficacy outcomes included clinical response during therapy (between days 3 and 5 after the start of therapy) and bacteriologic response at the test-of-cure visit.
Patients were considered to be eligible for the clinical efficacy analysis (i.e., for enrollment in the clinically valid population) if they met the eligibility criteria, received the study drug for у48 h (in cases of clinical failure) or for у5 days (in cases of clinical cure), received no other concomitant systemic antimicrobial therapy, had a test-of-cure clinical assessment that was not indeterminate, and had у80% adherence with study medication. Patients who met these criteria but discontinued receiving the study drug because of an adverse event were included in the efficacy analysis. Clinical response at the test-of-cure visit was defined as cure (disappearance of acute signs and symptoms related to the infection or sufficient improvement such that additional or alternative antimicrobial therapy was not required), failure (failure to respond or insufficient improvement of the signs and symptoms of infection such that additional antimicrobial therapy was required), or indeterminate. Clinical response at the during therapy visit (between days 3 and 5 after the start of therapy) was categorized as recovery (disappearance of acute signs and symptoms related to the infection or reduction in the severity and/or number of signs and symptoms of infection), failure (as defined above), or indeterminate.
Patients who were in the clinically valid population and had a pathogen isolated from sputum or blood culture before treatment comprised the microbiologically valid population. Bacteriologic responses during therapy and at the test-of-cure visit were defined as eradication, presumed eradication (if no sputum specimen was available because of clinical success), persistence, presumed persistence (no sputum specimen was available for patients with clinical failure), or indeterminate. Superinfection was defined as the appearance of a new pathogen in patients with clinical failure.
Safety and tolerability assessment. The safety analysis included patients who received at least 1 dose of study drug (intention-to-treat population). Adverse events were documented up to the test-of-cure visit using Medical Dictionary for Regulatory Activities (MedDra) terminology. Treatment-emergent adverse events (i.e., regardless of their relationship to study drug) and adverse reactions leading to premature discontinuation were recorded. Each adverse event was rated by the investigator on the basis of intensity (mild, moderate, or severe) and whether it was definitely, probably, or possibly related to the study drug. Serious adverse reactions were defined as those that were fatal, were life-threatening, required hospitalization, resulted in disability, or otherwise endangered the patient and were documented up to 30 days after receipt of the final dose of study drug. Serial blood and urine samples were collected throughout the study for routine hematologic, chemistry, and coagulation evaluations and for urinalysis. Health resource utilization assessment. Data on the total duration of hospital stay, duration of intensive care unit (ICU) stay, total duration of antimicrobial therapy, and duration of intravenous therapy were collected at the test-of-cure visit.
Statistical analysis. All statistical analyses were performed using SAS (SAS Institute) [13] . The primary efficacy objective was to show that moxifloxacin therapy was not inferior to levofloxacin therapy for the treatment of CAP, on the basis of clinical response at the test-of-cure visit for the clinically valid population. The power calculation for this end point was based on the Farrington-Manning method: assuming a clinical success rate of 90% and an eligibility of 70% for the enrolled subjects, a total of 400 enrolled patients provides 280 patients (400 ) in the clinically valid population, giving a patients ϫ 70% power of 76% by using a D (critical difference) of Ϫ10% or a power of 90% by using a D of Ϫ15%. The Cochran-MantelHaenszel method was used to calculate 95% CIs [14] . Secondary efficacy end points included clinical outcome at other time points in the intention-to-treat and microbiologically valid populations, as well as bacteriologic outcomes.
Logistic regression was performed to evaluate treatment effect on the primary dependent efficacy outcome variable (i.e., ). B, Clinical cure at the test-of-cure visit (i.e., primary efficacy outcome); † 95% CI for difference, Ϫ1.9 to P p .01 11.9 ( ). P p .2 clinical response at the test-of-cure visit) after adjusting for risk factors, including sex, race, age, pretreatment hospitalization history, pneumonia severity index score, switch from intravenous to oral treatment, sequence of intravenous dosing, smoking history, primary residence, presence of pathogen at baseline, body mass index, infection duration, aspiration pneumonia, and health status. Multiple logistic regression was performed with only those variables with P values of !.20. Treatment effect was evaluated after adjusting for other confounding factors in the regression model from the univariate analyses. Continuous independent variables were treated as continuous, with no collapsing done for the analysis.
Demographic and clinical characteristics at baseline, adverse events, and laboratory data were summarized using descriptive statistics, and treatment groups were compared using 1-way analysis of variance for continuous variables or x 2 analysis for categorical data.
RESULTS
Patient disposition and demographic characteristics.
Of 401 patients randomly assigned to receive study therapy, 7 received no study medication. Thus, the safety population included 394 patients (figure 1). The clinically valid population included 141 patients in the moxifloxacin group and 140 patients in the levofloxacin group. Baseline demographic and clinical characteristics for the clinically valid population are summarized in table 1 and were similar between the 2 treatment groups. The clinically valid population had a mean age (‫ע‬SD) of years, with 77.9 ‫ע‬ 7.1 For the clinically valid population, the mean duration (‫ע‬SD) of total antimicrobial therapy was days for the mox-10.0 ‫ע‬ 2.7 ifloxacin arm and days for the levofloxacin arm 10.0 ‫ע‬ 2.9 ( ). The mean duration (‫ע‬SD) of intravenous therapy was P 1 .8 days for the moxifloxacin arm versus days 3.7 ‫ע‬ 2.0 3.8 ‫ע‬ 2.2 for levofloxacin arm ( ). The majority of patients were P p .7 switched to oral therapy on day 3 or 4 after the start of therapy (93.6% in the moxifloxacin arm vs. 88.6% in the levofloxacin arm;
). P p .2 Clinical outcomes. At the test-of-cure visit, the clinical cure rate (i.e., the primary efficacy outcome) for the clinically valid population was 92.9% for the moxifloxacin arm and 87.9% for the levofloxacin arm (95% CI, Ϫ1.9 to 11.9; ) (figure P p .2 2). At the during treatment visit (between days 3 and 5 after the start of therapy) for the clinically valid population, 97.9% of patients in the moxifloxacin arm, compared with 90.0% of patients in the levofloxacin arm, had achieved clinical recovery (95% CI, 1.7-14.1; ) (figure 2). P p .01 Univariate analysis identified the following risk factors as influences of clinical outcome (figure 3): for severe CAP, the rates of clinical cure were 94.7% in the moxifloxacin arm and 84.6% in the levofloxacin arm (95% CI, Ϫ0.12 to 0.32; P p ); for patient age, the clinical cure rates for those aged 65-.5 74 years were 90.0% in the moxifloxacin arm and 85.0% in the levofloxacin arm (95% CI, Ϫ0.09 to 0.19;
), and the P p .6 rates for those aged у75 years were 94.5% and 90.0%, respectively (95% CI, Ϫ0.05 to 0.14; ); and patients who P p .4 were still receiving intravenous therapy at the test-of-cure visit had lower clinical cure rates (55.6% [ ). P p .98 Safety and tolerability. The rate of treatment-emergent adverse events due to any cause was significantly higher in the moxifloxacin-treated patients ( ) (table 3) , although the P p .01 rates of drug-related and serious adverse events were similar for both treatment arms. There was no difference between treatments with regard to the rate of premature discontinuation owing to an adverse event; 17 (48.6%) of 35 of these events were considered to be drug related (10 in the moxifloxacin arm and 7 in the levofloxacin arm). Serious adverse events were reported for ∼23% of patients in both treatment groups ( ). No clinically significant differences between treatment P p .9 groups were seen for clinical laboratory test values or vital signs.
There was no difference in mortality between the 2 treatment groups ( ), and the majority of deaths occurred 17 days P p .5 after receipt of the final dose of study drug. Only 6 moxifloxacin-and 3 levofloxacin-treated patients died during therapy or within the first 7 days after therapy. None of the deaths were considered to be drug related, and all were determined by the investigators to be due to the patient's comorbid diseases.
Health resource utilization. For the clinically valid population, the total duration of hospital stay (‫ע‬SD) was 7.5 ‫ע‬ days in the moxifloxacin arm and days in the 4.2 7.5 ‫ע‬ 4.6 levofloxacin arm ( ), with a mean duration (‫ע‬SD) of P p .95 days and days, respectively, for hospital stay 6.8 ‫ע‬ 4.1 6.8 ‫ע‬ 4.6 after the initiation of study drug treatment ( ). For pa-P p .95 tients in the ICU, the total duration of hospital stay was similar between the treatment groups. There were no differences in health resource utilization between patients with positive versus those with negative results of pretherapy bacterial cultures. 
DISCUSSION
In this prospective, randomized, double-blind trial involving hospitalized elderly patients with CAP, moxifloxacin-treated patients were more likely to have clinical improvement by treatment day 3-5 than were levofloxacin-treated patients. The overall clinical cure rate and bacteriologic success rates were similar between the 2 treatment groups. There was a higher incidence of adverse events due to any cause in the moxifloxacin group, although the incidence of drug-related adverse events was similar to that in the levofloxacin group. In subgroup analyses based on CAP severity and patient age, clinical cure rates in the moxifloxacin arm were consistently higher than, although not statistically significantly different from, those for levofloxacin. This trial included 394 elderly patients with a mean age (‫ע‬SD) of years, 60.9% of whom were at least 75 77.4 ‫ע‬ 7.7 years old. Most patients had concomitant comorbid conditions, including cardiac, gastrointestinal, chronic lung disease, and diabetes mellitus. More than two-thirds of patients in both groups had a pneumonia severity index score of у3. The pneumonia severity index score is high for this population probably because this measure is strongly influenced by age [12] .
Clinical trials involving adults have demonstrated that moxifloxacin is effective against CAP [15] [16] [17] [18] . In very elderly patients with CAP (age, 175 years), a pooled analysis of 5 prospective, randomized, controlled trials of intravenous and oral moxifloxacin therapy found similar efficacy and adverse event rates to those observed in the current trial [19] . Comparator agents were clarithromycin and amoxicillin in the oral treatment studies and trovafloxacin, levofloxacin, and amoxicillin/ clavulanate with or without clarithromycin in the intravenous treatment studies [19] . The overall clinical success rates were 93.0% (53 of 57 patients) and 90.2% (83 of 92 patients) for the oral and intravenous moxifloxacin arms, respectively (95% CI, Ϫ3.2 to 15.9), and 86.4% (38 of 44 patients) and 83.7% (77 of 92 patients) for the oral and intravenous comparator arms, respectively (95% CI, Ϫ5.4 to 20.9) [19] .
Recently, Dunbar et al. [20] reported similar efficacy and safety outcomes between 2 levofloxacin doses (500 mg vs. 750 mg, once daily) for treatment of mild or severe CAP in adult patients. However, the present study is the first comparative evaluation of 2 different fluoroquinolones in hospitalized elderly patients with CAP. The finding that moxifloxacin therapy led to a significantly more rapid clinical improvement and/or resolution of pneumonia than levofloxacin therapy in elderly patients (i.e., between days 3 and 5 after the start of therapy) may be clinically important. This end point should be considered for other CAP clinical trials because it may represent a more sensitive measure of antibiotic efficacy than assessment at the test-of-cure visit. However, it should be noted that, in the current study, there were no differences in duration of stay or duration of intravenous therapy between the 2 regimens. This could, at least in part, be due to the minimum duration of therapy (5 days) mandated by the protocol for patients to be considered for the clinically valid population, and the fact that the total duration of hospitalization in this patient population could have been influenced by other factors, including multiple comorbidities present in these patients.
The rate of treatment-emergent adverse events was significantly higher in the moxifloxacin arm, compared with the levofloxacin arm. However, the rates of drug-related and serious adverse events were similar for both treatment arms. It is possible that the higher rate of adverse events due to any cause was caused by high rates of underlying comorbid illness, including cardiac disease. Moxifloxacin-treated patients experienced fewer drug-related cardiac adverse events than did levofloxacin-treated patients, although this difference was not statistically significant (1.0% vs. 3.5%;
). Diarrhea and P ! .2 oral candidiasis were the 2 most commonly reported drugrelated adverse events in both treatment groups. There was no evidence that moxifloxacin therapy increased the risk of Clostridium difficile diarrhea in elderly patients more than levofloxacin did; there were more occurrences of C. difficile colitis in the levofloxacin arm (6 patients [3.0%]) than in the moxifloxacin arm (1 patient [0.5%]), although the difference was not statistically significant ( ). Recent publications sug-P p .1 gest that fluoroquinolones may increase the risk of C. difficile colitis [21] and may reduce the effectiveness of subsequent antimicrobial therapy [22] . One study in a long-term care facility showed that gatifloxacin therapy may be associated with a higher rate of C. difficile diarrhea than levofloxacin therapy [21] .
Twenty-six patients died during the observation period; most deaths were associated with the severity of comorbid diseases. The mortality rate in this study is lower than those reported elsewhere for hospitalized patients with CAP, which range from 10% to 40% [1, 2, 7, 8] . This difference may be due to the eligibility criteria for this study, which excluded patients who required mechanical ventilation or vasopressors or who had multiorgan failure.
An important limitation of this study is that the etiology of CAP could not be identified in the majority of patients. Pneumococcal urine antigen testing and serologic testing for detection of atypical organisms were not performed. Thus, correlation of clinical outcomes with bacteriologic outcomes was not possible for most patients. Also, antimicrobial susceptibility data were not available for all cultured organisms. The organisms isolated most commonly were Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus, as reported by other investigators [2, 8] .
In conclusion, sequential intravenous/oral moxifloxacin monotherapy provided significantly higher clinical recovery rates by day 3-5 after initiation of treatment and was as effective, safe, and well tolerated as intravenous/oral levofloxacin monotherapy in hospitalized elderly patients with CAP. Prospective studies are needed to identify the factors associated with duration of antibiotic therapy and hospital stay in this patient population.
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